<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cryptococcus neoformans: Treatment of meningoencephalitis and disseminated infection in patients without HIV</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cryptococcus neoformans: Treatment of meningoencephalitis and disseminated infection in patients without HIV</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cryptococcus neoformans: Treatment of meningoencephalitis and disseminated infection in patients without HIV</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gary M Cox, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John R Perfect, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Most patients with cryptococcal meningoencephalitis are immunocompromised. The most common forms of immunosuppression other than human immunodeficiency virus (HIV) include glucocorticoid therapy, biologic modifiers, the use of some tyrosine kinase inhibitors (eg, <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">ibrutinib</a>), solid organ transplantation, cancer (particularly hematologic malignancy), and conditions such as sarcoidosis and hepatic failure. For many patients in these risk groups, the clinical presentation is variable. Some patients have symptoms for up to several months prior to diagnosis, whereas others present with an acute illness of only a few days. Typically, headache, lethargy, personality changes, and memory loss develop over two to four weeks. Patients may also present with disseminated disease to other body sites.</p><p>Issues related to treatment of <em>Cryptococcus neoformans</em> in patients without HIV will be reviewed here. Other topic reviews related to cryptococcal disease include:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2448.html" rel="external">"Microbiology and epidemiology of Cryptococcus neoformans infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2447.html" rel="external">"Clinical manifestations and diagnosis of Cryptococcus neoformans meningoencephalitis in patients without HIV"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2421.html" rel="external">"Cryptococcus neoformans infection outside the central nervous system"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3757.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in patients with HIV"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/85376.html" rel="external">"Clinical management and monitoring during antifungal therapy for cryptococcal meningoencephalitis in persons with HIV"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16624.html" rel="external">"Cryptococcus gattii infection: Microbiology, epidemiology, and pathogenesis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/85842.html" rel="external">"Cryptococcus gattii infection: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/90020.html" rel="external">"Cryptococcus gattii infection: Treatment"</a>.)</p><p></p><p class="headingAnchor" id="H2340724683"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>Patients with cryptococcal meningoencephalitis require a prolonged course of antifungal therapy (induction, consolidation, and maintenance phases) [<a href="#rid1">1,2</a>]. Additional therapeutic interventions include managing intracranial pressure, reducing immunosuppressive therapy, and controlling immune reconstitution inflammatory syndromes (IRIS). (See <a class="local">'Control of intracranial pressure'</a> below and <a class="local">'Modulating immunosuppression'</a> below and <a class="local">'Immune reconstitution inflammatory syndrome'</a> below.) </p><p>Patients with severe pulmonary disease (eg, diffuse pulmonary infiltrates) or disseminated disease (eg, involvement of at least two noncontiguous sites) should be treated with the same antifungal regimens as those used to treat central nervous system disease, even in the setting of normal findings on cerebrospinal fluid examination. (See  <a class="medical medical_review" href="/z/d/html/2421.html" rel="external">"Cryptococcus neoformans infection outside the central nervous system"</a>.)</p><p class="headingAnchor" id="H553666855"><span class="h1">ANTIFUNGAL THERAPY</span><span class="headingEndMark"> — </span>Antifungal agents used for the treatment of cryptococcal meningoencephalitis typically include amphotericin B, <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a>, and <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>. The drug-drug interactions (eg, azoles and calcineurin inhibitors or <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>) and the adverse effects associated with these agents must be assessed carefully in the setting of cryptococcal infections. Refer to the Lexicomp drug information topics within UpToDate and the discussion of patient monitoring below for specific information. (See <a class="local">'Monitoring for toxicity'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h2">Induction antifungal therapy</span><span class="headingEndMark"> — </span>The preferred antifungal regimen for induction therapy for patients without HIV are largely extrapolated from larger studies of patients with HIV infection. (See  <a class="medical medical_review" href="/z/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention"</a>.) </p><p class="headingAnchor" id="H2039088809"><span class="h3">Preferred regimen</span><span class="headingEndMark"> — </span>For nonpregnant adults, we suggest that induction therapy consist of a lipid formulation of amphotericin B <strong>plus</strong> <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>Either <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> (3 to 4 mg/kg intravenously [IV] per day) or <a class="drug drug_general" data-topicid="8724" href="/z/d/drug information/8724.html" rel="external">amphotericin B lipid complex</a> (5 mg/kg IV per day) can be used. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">Flucytosine</a> should be administered as 100 mg/kg/day orally in four divided doses (adjusted for renal function). (See  <a class="medical medical_review" href="/z/d/html/472.html" rel="external">"Pharmacology of flucytosine (5-FC)", section on 'Dosing'</a>.)</p><p></p><p>This regimen should be administered for at least two weeks. However, for some patients the duration should be extended for four to six weeks. (See <a class="local">'Duration of preferred regimen'</a> below.)</p><p>Specific treatment considerations for pregnant women, children, and those with cryptococcomas, and information regarding patient monitoring, are discussed below. (See <a class="local">'Special populations'</a> below and <a class="local">'Monitoring for toxicity'</a> below.)</p><p class="headingAnchor" id="H861556618"><span class="h4">Rationale</span><span class="headingEndMark"> — </span>There are no controlled treatment trial data on lipid formulations and <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> together for the treatment of cryptococcal meningitis. Thus, the rationale for this approach is as follows: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of liposomal preparations</strong> – Lipid formulations of amphotericin B, rather than <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>, are preferred as first-line therapy in organ transplant recipients due to the frequency of reduced renal function in such patients (approximately 25 percent have creatinine &gt;2 mg/dL) and the risk of nephrotoxicity associated with concurrent use of amphotericin B deoxycholate and calcineurin inhibitors. In a prospective cohort study of 75 solid organ transplant recipients with central nervous system (CNS) cryptococcosis who were treated with amphotericin B, those who received a lipid formulation had a lower 90-day mortality on multivariate analysis than those who received the deoxycholate formulation (odds ratio 0.11, 95% CI 0.02-0.57) [<a href="#rid3">3</a>]. In addition, <a class="drug drug_general" data-topicid="8724" href="/z/d/drug information/8724.html" rel="external">amphotericin B lipid complex</a> has been used successfully for cryptococcal meningoencephalitis in salvage regimens and is also acceptable for patients with amphotericin B deoxycholate toxicity [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1">There are fewer data regarding the use of lipid formulations of amphotericin B preparations in nontransplant patients. The 2010 Infectious Disease Society of America (IDSA) guidelines suggest that induction therapy for nontransplant patients without HIV and with cryptococcal meningoencephalitis consists of <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (0.7 to 1 mg/kg IV daily) plus <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> (100 mg/kg/day orally in four divided doses). However, lipid formulations of amphotericin B with flucytosine have become the favored induction regimen for such patients in resource-available health care systems to minimize the risk of toxicity and reduce treatment interruptions, since it is critically important to complete an uninterrupted induction regimen to optimize clinical outcomes [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination therapy with </strong><a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> – Flucytosine is used as an adjunct to amphotericin B for the first two weeks of therapy because the combination of agents provides greater early fungicidal activity than amphotericin B alone [<a href="#rid6">6-9</a>]. The absence of flucytosine is associated with lack of cerebrospinal fluid (CSF) sterilization at week two and treatment failure [<a href="#rid10">10,11</a>]. Combination therapy with amphotericin B plus flucytosine also results in lower mortality compared with amphotericin B monotherapy or combination therapy with amphotericin B plus <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> [<a href="#rid8">8,9</a>]. </p><p></p><p class="bulletIndent1">Most of the data regarding the use of <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> are from studies of patients with HIV. In the cohort study of solid organ transplant recipients described above, there was no difference in mortality between patients who received lipid formulations of amphotericin B with or without flucytosine [<a href="#rid3">3</a>]. However, the number of patients who received flucytosine may have been inadequate to provide meaningful results. </p><p></p><p class="headingAnchor" id="H1351839573"><span class="h3">Duration of preferred regimen</span><span class="headingEndMark"> — </span>The minimum duration of induction therapy with amphotericin B and <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> is two weeks. However, the ultimate duration depends upon the presence of serious neurologic complications (eg, persistent headaches, seizures, ocular and auditory manifestations), radiographic evidence of brain parenchymal involvement (eg, cryptococcomas), the patient's underlying condition, and the response to therapy. (See <a class="local">'Patients without neurologic complications'</a> below and <a class="local">'Patients with neurologic complications'</a> below and <a class="local">'Patients with cryptococcomas'</a> below.)</p><p>After induction therapy is completed, patients should be transitioned to consolidation therapy, then a maintenance regimen. (See <a class="local">'Consolidation and maintenance therapy'</a> below.)</p><p class="headingAnchor" id="H4171422610"><span class="h4">Patients without neurologic complications</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunocompromised hosts</strong> – For immunocompromised hosts without neurologic complications or parenchymal involvement, a repeat lumbar puncture (LP) is typically performed after two weeks of induction therapy, and the response to therapy is assessed by the presence or absence of fungal growth [<a href="#rid8">8,12</a>]. Serial evaluation of CSF or serum cryptococcal antigen (CrAg) is not appropriate for evaluating response to therapy as CrAg does not correlate with CSF sterilization at two weeks or outcome at 180 days [<a href="#rid2">2,13,14</a>]. </p><p></p><p class="bulletIndent1">However, it can take several weeks for culture results to be finalized, and this delay makes decision-making difficult when determining the ultimate duration of treatment. Thus, we use certain prognostic factors to dictate the treatment approach while awaiting culture results. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We transition patients to consolidation therapy pending the results of the two-week CSF cultures if the cultures are anticipated to be negative based upon a clear clinical response to treatment and favorable baseline CSF studies, such as a CrAg titer ≤1:160 [<a href="#rid1">1</a>]. </p><p></p><p class="bulletIndent2">This approach has generally been used for organ transplant recipients. In a small prospective study of CNS cryptococcosis in transplant patients, the median time to CSF sterilization was 10 days (mean, 16 days) [<a href="#rid14">14</a>]. Guidelines have typically favored a four-week induction course for nontransplant patients without HIV because they tend to have a worse clinical outcome [<a href="#rid1">1,15,16</a>] (see <a class="local">'Prognosis'</a> below); however, we feel a two-week induction course is reasonable for such patients who have had a rapid response. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For all others, we continue the induction regimen pending the results of the cultures. If the cultures are negative at two weeks, the patient can then be transitioned to consolidation therapy. Although laboratories often keep cultures for three to four weeks to detect fungal growth, most persistently positive cryptococcal cultures grow within two weeks in patients who are on therapy. </p><p></p><p class="bulletIndent1">Patients whose CSF cultures return positive should reinitiate (or continue) the induction regimen with serial lumbar punctures every two weeks until the CSF becomes sterile.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunocompetent hosts</strong> – On occasion, cryptococcal meningoencephalitis can occur in patients with no apparent underlying condition [<a href="#rid17">17</a>]. Immunocompetent hosts who have severe symptoms at presentation should be managed the same way as those who are immunocompromised, as described above.</p><p></p><p class="bulletIndent1">However, certain immunocompetent hosts may transition to consolidation therapy without a repeat LP at two weeks. Such patients include those who were without severe symptoms at baseline, were diagnosed early, did not develop new symptoms, and demonstrated a clear clinical response after two weeks of combination antifungal therapy. In this setting, it is reasonable to administer a two-week induction course, and then transition to consolidation therapy with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> at a high dose (800 mg [12 mg/kg] per day orally) for eight weeks [<a href="#rid1">1</a>]. (See <a class="local">'Consolidation and maintenance therapy'</a> below.)</p><p></p><p class="headingAnchor" id="H934398158"><span class="h4">Patients with neurologic complications</span><span class="headingEndMark"> — </span>For individuals who have or develop neurologic complications on treatment, induction therapy should be extended for at least six weeks (or four weeks after the culture is negative) [<a href="#rid18">18</a>]. The management of patients with cryptococcomas is described below. (See <a class="local">'Patients with cryptococcomas'</a> below.)</p><p class="headingAnchor" id="H2148164925"><span class="h3">Alternative regimens</span><span class="headingEndMark"> — </span>Alternative regimens are used when patients cannot tolerate <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> and/or amphotericin B, or when a specific agent is not available. </p><p class="bulletIndent1"><span class="glyph">●</span>If <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> is not available or tolerated, we typically administer amphotericin B with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (800 mg [12 mg/kg] per day orally) for two weeks of induction therapy. </p><p></p><p class="bulletIndent1">Other options include extending the duration of amphotericin B so that patients receive at least four to six weeks of induction therapy [<a href="#rid1">1</a>], or, in cases with a high fungal burden of disease (or relapse), administering higher doses of <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> (6 mg/kg/day). However, these alternative approaches are not ideal. As an example, extending the duration of amphotericin B is more likely to be associated with toxicity compared with using combination therapy. In addition, a randomized controlled trial that compared doses of 3 mg/kg and 6 mg/kg of liposomal amphotericin B in patients with acquired immunodeficiency syndrome (AIDS) found that the higher dose was safe, but not more efficacious than the lower dose [<a href="#rid19">19</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If lipid formulations of amphotericin B are not available, <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (0.7 mg/kg/day) should be used. This agent is known to be effective for the treatment of cryptococcal disease and is generally well tolerated for two weeks when administered with adjunctive <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> infusions [<a href="#rid6">6,7,20</a>]. (See  <a class="medical medical_review" href="/z/d/html/476.html" rel="external">"Pharmacology of amphotericin B", section on 'Amphotericin B deoxycholate'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If no amphotericin B formulations are tolerated or available, <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (800 to 1200 mg orally per day) plus <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> (100 mg/kg orally per day in four divided doses) can be administered for the two-week induction period. This regimen can also be continued until two-week CSF culture returns negative and/or up to 10 weeks in severe cases [<a href="#rid1">1,21-23</a>]. Liver function tests should be monitored closely when this combination is used. (See <a class="local">'Monitoring for toxicity'</a> below.)</p><p></p><p class="bulletIndent1">If <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> cannot be given, higher doses of <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (eg, 1200 mg orally per day in patients with normal renal function) can be administered for at least 10 weeks or until CSF culture results are negative, followed by maintenance therapy with fluconazole (200 to 400 mg orally daily). However, fluconazole monotherapy for induction therapy is generally not recommended. </p><p></p><p class="headingAnchor" id="H5"><span class="h2">Consolidation and maintenance therapy</span><span class="headingEndMark"> — </span>Following induction therapy, consolidation therapy with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> 800 mg (or 12 mg/kg in children) orally daily should be administered for eight weeks. </p><p>Consolidation therapy should then be followed by maintenance therapy with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (200 to 400 mg orally daily) [<a href="#rid1">1</a>]. Maintenance azole therapy is generally given for one year after diagnosis. Longer therapy may be warranted for those receiving very high doses of immunosuppressive agents (eg, those receiving &gt;40 mg/day of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or persistently using biologic modifiers such as <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>); for such patients, the duration of maintenance therapy is determined on a case-by-case basis. Maintenance therapy may also need to be extended for those who have radiographic evidence of cryptococcomas. (See <a class="local">'Patients with cryptococcomas'</a> below.)</p><p>Prior to the use of <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> for maintenance therapy, the rate of relapse of cryptococcal meningoencephalitis in patients without HIV ranged from 15 to 25 percent; most relapses occurred within six months [<a href="#rid18">18</a>]. The use of consolidation and maintenance therapy has been associated with a very low relapse rate. As an example, in a prospective study of 79 solid organ transplant recipients in whom maintenance therapy was employed for a median of 183 days, the risk of relapse was 1.3 percent [<a href="#rid14">14</a>]. </p><p class="headingAnchor" id="H2356532668"><span class="h2">Special populations</span></p><p class="headingAnchor" id="H287714271"><span class="h3">Pregnant women</span><span class="headingEndMark"> — </span>For pregnant women, it is reasonable to administer induction therapy for four weeks. Antifungal treatment should be continued throughout pregnancy. Immunologic alterations associated with pregnancy may increase the severity of cryptococcosis in pregnant women, and the mortality rate can approach 25 percent [<a href="#rid24">24</a>]. In addition, immune reconstitution inflammatory syndrome (IRIS) can occur in the postpartum period [<a href="#rid25">25,26</a>]. Indeed, nearly half of the cryptococcal cases reported in pregnancy presented with symptomatic disease in the third trimester or postpartum period [<a href="#rid24">24</a>]. (See <a class="local">'Immune reconstitution inflammatory syndrome'</a> below and  <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a>.)</p><p>The specific regimen should be tailored to the stage of pregnancy.</p><p class="bulletIndent1"><span class="glyph">●</span>Initial treatment of pregnant women with CNS or disseminated disease consists of <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (0.7 to 1.0 mg/kg IV daily) or a lipid formulation of amphotericin B (<a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> [3 to 4 mg/kg IV daily] or <a class="drug drug_general" data-topicid="8724" href="/z/d/drug information/8724.html" rel="external">amphotericin B lipid complex</a> [5 mg/kg IV daily]) [<a href="#rid1">1</a>]. </p><p></p><p class="bulletIndent1">There are no prospective data to guide which preparation should be used in this setting, and experience is limited. We would favor conventional amphotericin B, but if nephrotoxicity or other toxicities become an issue, clinicians should feel comfortable using a lipid formulation of amphotericin B instead. Although there is much more experience with <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>, and the deoxycholate formulation is known to be well distributed in the placenta [<a href="#rid27">27</a>], the liposomal preparations appear safe in pregnancy, and there is some anecdotal experience treating cryptococcal meningoencephalitis with this agent during pregnancy [<a href="#rid28">28</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">Flucytosine</a> should <strong>not</strong> be used during the first trimester of pregnancy. If the patient presents during the second or third trimester, the use of flucytosine should be determined on a case-by-case basis. Although this agent has been used to treat cryptococcosis in the second and third trimesters and has not been associated with adverse outcomes, the literature is limited to case series [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/z/d/html/472.html" rel="external">"Pharmacology of flucytosine (5-FC)", section on 'Pregnancy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For consolidation therapy, it is appropriate to administer <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> during the second and third trimesters to ensure continuous antifungal therapy. However, fluconazole should be avoided during the first trimester since it has been associated with congenital anomalies [<a href="#rid30">30,31</a>]. The only alternative for continuous antifungal therapy during pregnancy is amphotericin B. A more detailed discussion of the use of azoles during pregnancy is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Pregnancy'</a>.)</p><p></p><p class="headingAnchor" id="H244693705"><span class="h3">Children</span><span class="headingEndMark"> — </span>Cryptococcosis has been reported in children with primary immunodeficiencies such as hyper-immunoglobulin M syndrome and severe combined immunodeficiency syndrome. It can also occur in children with HIV, connective tissue diseases, and in solid organ transplant recipients. Cryptococcosis has also been described in children with no recognized immunodeficiency.</p><p>Treatment of children with CNS or disseminated disease consists of an amphotericin B formulation (<a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> [1.0 mg/kg IV daily], <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> [5 to 7.7 mg/kg/day], or <a class="drug drug_general" data-topicid="8724" href="/z/d/drug information/8724.html" rel="external">amphotericin B lipid complex</a> [5 mg/kg/day]) plus <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> (100 mg/kg orally per day in four divided doses) for two weeks, followed by <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (10 to 12 mg/kg orally per day) for a minimum of eight weeks [<a href="#rid1">1</a>]. Amphotericin B plus fluconazole can be administered for the induction phase if flucytosine cannot be used [<a href="#rid32">32</a>]. </p><p><a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">Flucytosine</a> can cause myelosuppression; monitoring of flucytosine levels and blood counts should be performed [<a href="#rid33">33</a>]. The American Academy of Pediatrics suggests that flucytosine peak concentrations (two hours after a dose) should be maintained between 40 and 60 mcg/mL [<a href="#rid32">32</a>]. </p><p>Literature concerning pediatric cryptococcosis is limited to small series, and treatment recommendations are based on extrapolation of studies in adults. The dose of <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> ranges from 0.5 to 1 mg/kg IV daily; children generally tolerate this agent better than adults and a dose of 1 mg/kg per day is commonly used [<a href="#rid34">34</a>]. Successful treatment of <em>Cryptococcus</em> in children using <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> has been reported at daily doses of 5 to 7.5 mg/kg daily [<a href="#rid35">35,36</a>]. <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">Fluconazole</a> dosing is higher in children than adults as the volume of distribution is larger and the clearance is more rapid [<a href="#rid37">37,38</a>].</p><p class="headingAnchor" id="H671603793"><span class="h3">Patients with cryptococcomas</span><span class="headingEndMark"> — </span>Cerebral cryptococcomas can cause significant morbidity, are difficult to treat, and require prolonged antifungal therapy [<a href="#rid39">39,40</a>]. They are more common in the setting of <em>Cryptococcus gattii</em> infection than <em>C. neoformans</em> infection [<a href="#rid39">39,41,42</a>]. The management of cryptococcomas associated with <em>C. gattii</em> infection is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/90020.html" rel="external">"Cryptococcus gattii infection: Treatment", section on 'Cerebral cryptococcomas'</a>.)</p><p>There are no prospective studies evaluating management of cerebral cryptococcomas; the approach to therapy is extrapolated from observational studies, literature addressing management of cryptococcal meningitis, and expert opinion [<a href="#rid17">17,40,43,44</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antifungal therapy</strong> – Induction therapy for cerebral cryptococcomas should consist of a lipid formulation of amphotericin B (<a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> [3 to 4 mg/kg IV daily] or <a class="drug drug_general" data-topicid="8724" href="/z/d/drug information/8724.html" rel="external">amphotericin B lipid complex</a> [5 mg/kg IV daily]) <strong>plus</strong> <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> (100 mg/kg per day orally in four divided doses) for at least six weeks [<a href="#rid1">1</a>]. Consolidation and maintenance therapy for cerebral cryptococcoma consists of <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (400 to 800 mg orally daily) for 18 months.</p><p></p><p class="bulletIndent1">The duration of therapy depends on the clinical and radiographic response. Some brain lesions persist radiographically for long periods and/or develop surrounding edema during effective antifungal therapy, presumably because of an immunological response associated with control of infection [<a href="#rid45">45</a>]. Prolonged therapy and repeated induction courses may be warranted in some cases, even when <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> is used for consolidation [<a href="#rid17">17</a>]. </p><p></p><p class="bulletIndent1">Patients who do not respond to therapy should undergo biopsy or aspiration if the diagnosis was not confirmed initially, since severely immunosuppressed patients may have masses due to causes other than <em>Cryptococcus</em>. (See  <a class="medical medical_review" href="/z/d/html/3718.html" rel="external">"Approach to the patient with HIV and central nervous system lesions"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive therapies</strong> – Glucocorticoids may be administered in the setting of mass effect and surrounding edema, especially if there are neurologic deficits. If glucocorticoids are used, the doses should be tapered gradually to prevent "a rebound" IRIS. (See <a class="local">'Immune reconstitution inflammatory syndrome'</a> below.)</p><p></p><p class="bulletIndent1">Surgical removal (open or stereotactic guided) may be necessary for large (≥3 cm) lesions and lesions with mass effect with substantial surrounding edema. Surgery may also be needed in the setting of optic nerve involvement and in cases unresponsive to prolonged or repeated induction antifungal therapy [<a href="#rid40">40,45,46</a>]. Shunting is indicated for symptomatic hydrocephalus with dilated cerebral ventricles [<a href="#rid47">47</a>]. All surgical specimens, particularly enlarging lesions not explained by IRIS, should be submitted for histopathologic examination. </p><p></p><p class="headingAnchor" id="H561453088"><span class="h2">Monitoring for toxicity</span><span class="headingEndMark"> — </span>It is important to monitor for signs of toxicity throughout the duration of antifungal therapy. The type of monitoring depends upon which agents are used.</p><p class="bulletIndent1"><span class="glyph">●</span>Amphotericin B – Although the lipid formulations of amphotericin B are less toxic than conventional amphotericin B, monitoring for toxicity should mirror that used for <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>, with daily monitoring of blood counts and chemistries. In patients who develop renal dysfunction despite appropriate hydration, transitioning off or interrupting polyene therapy becomes a bedside decision. In general, the risks and benefits of switching to an alternative regimen should be considered when creatinine levels rise above 3 mg/dL in a patient with initial normal kidney function. (See <a class="local">'Alternative regimens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">Flucytosine</a> – Careful attention to serum flucytosine (5-FC) levels is also warranted to avoid bone marrow toxicity, particularly in patients with renal dysfunction. Measurement of serum 5-FC concentrations is recommended, when available, after three to five doses, and should be obtained two hours after a dose has been administered [<a href="#rid1">1</a>]. Guidelines for the treatment of cryptococcal infections recommend peak concentrations between 30 and 80 mcg/mL; concentrations &gt;100 mcg/mL should be avoided [<a href="#rid1">1</a>]. Serum drug concentrations should be repeated if renal function worsens, or if leukopenia or thrombocytopenia occur. With decreasing renal function (often due to amphotericin B), toxicity is more common and patients must be monitored carefully. If amphotericin B-induced nephrotoxicity occurs, the dose of 5-FC should be reduced. (See  <a class="medical medical_review" href="/z/d/html/472.html" rel="external">"Pharmacology of flucytosine (5-FC)", section on 'Serum concentration monitoring'</a>.) </p><p></p><p class="bulletIndent1">All patients receiving 5-FC should undergo regular monitoring of complete blood counts (CBC). In settings in which serum 5-FC concentrations are not available, CBC monitoring two to three times per week provides an indirect method of screening for excessive dosing. An otherwise unexplained reduction in the neutrophil or platelet count may reflect 5-FC toxicity, and either the drug should be stopped or the dose reduced. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">Fluconazole</a> – Fluconazole is generally well tolerated; patients occasionally may develop rash or abnormal aminotransferases. Aminotransferase levels and symptoms should be monitored in patients on long-term therapy. The risk of drug-induced liver injury increases with high doses (eg, &gt;800 mg daily). (See  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Fluconazole'</a>.)</p><p></p><p>Additional discussions of how to prevent and manage toxicities associated with amphotericin B and 5-FC are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/476.html" rel="external">"Pharmacology of amphotericin B"</a> and  <a class="medical medical_review" href="/z/d/html/2364.html" rel="external">"Amphotericin B nephrotoxicity"</a> and  <a class="medical medical_review" href="/z/d/html/472.html" rel="external">"Pharmacology of flucytosine (5-FC)"</a>.)</p><p class="headingAnchor" id="H3349804803"><span class="h1">CONTROL OF INTRACRANIAL PRESSURE</span><span class="headingEndMark"> — </span>Control of intracranial pressure is one of the most critical determinants of outcome for cryptococcal meningoencephalitis [<a href="#rid18">18,48</a>]. The intracranial pressure should be measured at the time of initial lumbar puncture. If the pressure is ≥25 cm of cerebrospinal fluid (CSF) and there are symptoms of increased intracranial pressure during induction therapy, CSF drainage should be performed to reduce the pressure by 50 percent (if extremely high) or to a normal pressure of ≤20 cm [<a href="#rid1">1</a>].</p><p>Therapeutic lumbar drainage should be repeated daily in the setting of clinical symptoms and persistent pressure elevations ≥25 cm of CSF until stabilized for &gt;2 days. Temporary percutaneous lumbar drains or ventriculostomy may be appropriate for patients who require repeated lumbar punctures [<a href="#rid47">47,49</a>]. Ventriculoperitoneal shunting may be warranted if the patient is receiving appropriate antifungal therapy and more conservative measures to control increased intracranial pressure have failed [<a href="#rid47">47,50,51</a>]. In one series of 27 patients with obstructive hydrocephalus and cryptococcal meningoencephalitis, 63 percent had good outcomes following permanent shunt placement; outcomes were worse in those with Glasgow coma score &lt;9 [<a href="#rid51">51</a>].</p><p><a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">Mannitol</a> and <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">acetazolamide</a> are <strong>not</strong> appropriate agents for control of elevated intracranial pressure in the setting of cryptococcal meningoencephalitis [<a href="#rid52">52</a>]. In addition, there is no benefit of administering glucocorticoids, except in the setting of an immune reconstitution inflammatory syndrome (IRIS) [<a href="#rid48">48</a>]. (See <a class="local">'Immune reconstitution inflammatory syndrome'</a> below.)</p><p>This approach to managing increased intracranial pressure is extrapolated from literature describing patients with HIV with cryptococcal meningoencephalitis. Among 55 patients with CSF pressure &gt;35 cm, increased incidence of papilledema (29 percent) and impaired mentation (18 percent) were observed [<a href="#rid48">48</a>]. Among 12 patients who died in the first two weeks of therapy, 91 percent had baseline intracranial pressure ≥25 cm. Among the 161 patients treated by CSF lumbar drainage to reduce the pressure, there were fewer cases of clinical failure and patients reported relief of severe headache; recurrence of elevated pressure was associated with worsening symptoms.</p><p class="headingAnchor" id="H2974849988"><span class="h1">MODULATING IMMUNOSUPPRESSION</span><span class="headingEndMark"> — </span>Reducing immunosuppressive therapy may be beneficial for control of cryptococcal infection. As an example, tyrosine kinase inhibitors, such as <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">ibrutinib</a>, should be stopped until infection is shown to be controlled. However, in some patients, the benefit of reducing immunosuppressive therapy must be balanced with the potential for organ rejection and immune reconstitution [<a href="#rid53">53</a>]. (See <a class="local">'Immune reconstitution inflammatory syndrome'</a> below.)</p><p>The optimal approach to management of the immunosuppressive regimen in organ transplant recipients with cryptococcosis is uncertain. Reducing immunosuppressants over time in a step-wise fashion following initiation of antifungal therapy is appropriate [<a href="#rid54">54</a>]. It may be helpful to reduce corticosteroids before calcineurin inhibitors, since the latter class has direct anticryptococcal activity in vitro [<a href="#rid55">55,56</a>].</p><p>When making changes to an immunosuppressive regimen, the drug-drug interactions and adverse effects associated with these agents, particularly calcineurin inhibitors or <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, must be considered carefully in the setting of cryptococcal infections. Detailed information on drug interactions can be found in the <a class="external" href="/drug-interactions">drug interaction program</a> within UpToDate and within the individual topic reviews. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus"</a>.)</p><p class="headingAnchor" id="H2873570208"><span class="h1">PERSISTENT/WORSENING SYMPTOMS</span><span class="headingEndMark"> — </span>For patients with persistent or worsening symptoms, distinguishing between persistent or relapsed cryptococcal infection, immune reconstitution inflammatory syndrome (IRIS), and other infections or complications can be difficult [<a href="#rid54">54,57</a>]. (See <a class="local">'Persistent or relapsed infection'</a> below and <a class="local">'Immune reconstitution inflammatory syndrome'</a> below.)</p><p>Clinical manifestations, inflammatory cerebrospinal fluid (CSF) values, positive India ink exams, and positive cryptococcal antigen titer may be present in both IRIS and cryptococcal infection. The most important distinguishing feature is that patients with active infection have positive CSF cultures, whereas patients with IRIS have sterile CSF cultures. In a study where polymerase chain reaction (PCR) testing using a Biofire Film Array Meningitis/Encephalitis Panel was performed on eight patients with HIV and symptomatic recurrence of cryptococcal meningitis, a positive PCR was associated with relapse/persistence while a negative PCR was associated with no growth, suggesting that the symptoms might be an IRIS [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H275842162"><span class="h2">Persistent or relapsed infection</span><span class="headingEndMark"> — </span>Persistent infection refers to persistently positive CSF cultures after four weeks of appropriate antifungal therapy. Relapse of infection refers to resolution of infection followed by subsequent recurrence as demonstrated by both recovery of viable cryptococci from a sterile site and recrudescence of signs and symptoms at a previous site of disease. Most cases are attributable to inadequate primary therapy (dose and/or duration) or insufficient adherence to consolidation or maintenance <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> therapy.</p><p>Risk factors for relapse include [<a href="#rid59">59</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Low initial CSF white blood cell counts</p><p class="bulletIndent1"><span class="glyph">●</span>Persistently low CSF glucose concentration after four weeks of therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (≥20 mg) or equivalent that continues after completion of antifungal therapy</p><p></p><p>Initial management of persistent or relapsed infection should include evaluation of immunosuppressive therapy and management of increased intracranial pressure. (See <a class="local">'Control of intracranial pressure'</a> above and <a class="local">'Modulating immunosuppression'</a> above.) </p><p>Repeat induction phase therapy should be reinstituted for a longer course (4 to 10 weeks) and a repeat lumbar puncture should be performed after two weeks of therapy. The amphotericin B dose may also be increased; <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> has been used at 6 mg/kg intravenously (IV) daily for treating cryptococcal meningitis [<a href="#rid19">19</a>]; for <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>, the upper limit of the dosing range is 1 mg/kg IV daily. </p><p>The fungal isolates of patients who relapsed should be evaluated for changes in the minimum inhibitory concentration (MIC) from the original isolate; a ≥3-dilution difference suggests development of drug resistance. A <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> MIC of ≥16 mcg/mL or a <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> MIC of ≥32 mcg/mL has typically been considered resistant and alternative agents should be considered [<a href="#rid60">60</a>]. However, there are no validated MIC breakpoints for drug susceptibility in cryptococcosis, and on a practical basis, only isolates with extremely high MICs for fluconazole and flucytosine (ie, ≥64 mcg/mL) should probably be considered resistant. For these strains with very high MICs to azoles, increasing the dose of the azole alone is unlikely to be successful. In such cases, <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (1 mg/kg IV daily) or lipid formulations of amphotericin B (5 to 6 mg/kg IV daily) should be administered until CSF, blood, and/or other sites are sterile.</p><p>After induction therapy, pending in vitro susceptibility testing, salvage consolidation therapy with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (800 to 1200 mg orally daily) should be reinstituted if the isolate is shown to be susceptible. If the organism is not responding to fluconazole but has a low MIC to <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> (≤1 mcg/mL), then voriconazole can be administered (loading doses of 6 mg/kg IV twice daily or 400 mg orally twice daily on the first day, then 200 to 300 mg orally twice daily for 10 to 12 weeks). <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">Posaconazole</a> (loading dose of 300 mg orally twice daily on the first day, followed by 300 mg orally once daily thereafter) is an alternative but achieves poor levels in the CSF. <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">Isavuconazole</a> (200 mg three times daily for two days followed by 200 mg once daily) has also been reported to have antifungal activity in patients with cryptococcosis but achieves minimal levels in the CSF [<a href="#rid61">61</a>]. </p><p>There are limited data regarding <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a>, or <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">isavuconazole</a> for the treatment of cryptococcal meningoencephalitis [<a href="#rid61">61-63</a>]. Voriconazole and posaconazole have been used with variable success as salvage therapy for patients with HIV in open compassionate treatment trials. As an example, in those trials, 18 patients with refractory disease were treated with voriconazole; 39 percent were treated successfully and 55 percent had stabilization of disease [<a href="#rid62">62</a>]. Among 29 patients with refractory disease treated with posaconazole, 48 percent were treated successfully and 20 percent had stabilization of disease [<a href="#rid63">63</a>]. In one study that included nine patients with cryptococcosis who were treated with isavuconazole, six (67 percent) had a successful response [<a href="#rid61">61</a>]. </p><p>The use of interferon-gamma as adjunctive therapy during primary (not salvage) treatment has been evaluated; its efficacy was encouraging but not definitive [<a href="#rid64">64,65</a>]. It may be a reasonable consideration for use in truly refractory cases with persistent positive cultures.</p><p class="headingAnchor" id="H1452748713"><span class="h2">Immune reconstitution inflammatory syndrome</span><span class="headingEndMark"> — </span>Immune reconstitution inflammatory syndrome (IRIS) is a paradoxical worsening of an infectious process following restitution of immune function. Onset of IRIS in solid organ transplant recipients has been described at a mean of six weeks after initiation of antifungal therapy [<a href="#rid53">53</a>]. Manifestations may include fever, lymphadenitis, and signs and symptoms of meningitis. Acute respiratory distress syndrome can also be a manifestation of IRIS in immunocompromised individuals. (See  <a class="medical medical_review" href="/z/d/html/1637.html" rel="external">"Acute respiratory distress syndrome: Clinical features, diagnosis, and complications in adults"</a>.)</p><p>Distinguishing between IRIS, relapse or progression of cryptococcal infection, and other infections or complications can be difficult in severely immunocompromised individuals [<a href="#rid54">54,57</a>]. Clinical manifestations, inflammatory CSF values, positive India ink exams, and positive cryptococcal antigen titer may be present in both IRIS and cryptococcal infection. The most important distinguishing feature is that patients with active infection have positive CSF cultures, whereas patients with IRIS have sterile CSF cultures. Some studies suggest that PCR positivity in CSF may help predict positive cultures [<a href="#rid58">58</a>]. </p><p>Patients with IRIS should continue antifungal therapy. Those with minor manifestations can be managed with supportive care; symptoms frequently resolve spontaneously in days to weeks. </p><p>In the setting of central nervous system (CNS) inflammation with increased intracranial pressure and severe symptoms, glucocorticoids may be used. Glucocorticoids should be administered with concomitant antifungal therapy. </p><p>There are limited data to suggest a specific dosing regimen. Some providers administer <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, starting at a dose of approximately 0.3 mg/kg/day IV (20 to 24 mg IV for most normal and overweight patients) during week 1, and then tapering the dose over the course of six weeks (eg, 0.2 mg/kg/day IV during week 2; followed by oral administration of 0.1 mg/kg/day during week 3; 3 mg/day during week 4; 2 mg/day during week 5; and 1 mg/day during week 6) [<a href="#rid66">66</a>]. However, other clinicians empirically use <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, starting at approximately 1 mg/kg/day (60 to 80 mg/day for most normal and overweight patients) and then tapering over four to six weeks. </p><p>IRIS occurs most commonly in patients with HIV with initiation of antiretroviral therapy, although it has also been described in solid organ transplant recipients [<a href="#rid41">41,53,67-69</a>]. In one study of 89 solid organ transplant recipients with cryptococcosis, 14 percent developed signs and symptoms suggestive of IRIS [<a href="#rid69">69</a>]. CNS disease and discontinuation of a calcineurin inhibitor were independently associated with IRIS. Among patients with CNS disease, those with neuroimaging abnormalities were more likely to develop IRIS. (See  <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a>.)</p><p>In patients with no obvious underlying immune deficiencies, worsening of symptoms can also occur, despite mycologic control of the infection [<a href="#rid41">41,70,71</a>]. Investigators have labelled this aggravated immune response "post-infectious inflammatory response syndrome" (PIIRS) [<a href="#rid72">72</a>]. Patients with PIIRS respond to systemic courses of steroids just as patients with IRIS do.</p><p>These episodes of clinical worsening appear very similar to immune reconstitution syndromes, but because there was no obvious underlying immune defect that was "reconstituted," investigators have been trying to identify the pathophysiology involved in these cases. In one study that evaluated a select group of apparently immunocompetent patients, investigators found that clinical deterioration appeared to occur as a result of dissociation between macrophages and T cells, leading to persistent inflammation due to failure of the macrophages to clear antigen [<a href="#rid73">73</a>]. A subsequent study described six cases of cryptococcal spinal arachnoiditis, which developed in previously healthy individuals with cryptococcal meningoencephalitis [<a href="#rid70">70</a>]. These patients had negative cultures, elevated CSF inflammatory markers (SCD27 and SCD21), and an elevated neuronal damage marker, neurofilament light chain; corticosteroid therapy significantly improved symptoms </p><p class="headingAnchor" id="H135916236"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The most important prognostic factors are the nature of the underlying immunosuppression and/or the concurrent disease. As an example, relapse rates among solid organ transplant recipients are very low [<a href="#rid14">14</a>]; in contrast, the mortality rate in those with cirrhosis is extremely high [<a href="#rid71">71</a>]. In addition, patients with cryptococcal meningoencephalitis and an underlying malignancy have a shorter median survival rate than those with HIV infection (two versus nine months) [<a href="#rid74">74</a>]. The prognosis among patients with malignancy and liver disease is also worse than those with immunosuppression due to glucocorticoid therapy [<a href="#rid17">17</a>] or anti-granulocyte-macrophage colony stimulating factor auto-antibodies [<a href="#rid75">75</a>]. Other factors conferring poor prognosis include: positive India ink examination of the cerebrospinal fluid (CSF); CSF white blood cell count &lt;20/microL; initial CSF or serum cryptococcal antigen titer &gt;1:32; and/or high opening pressure on lumbar puncture [<a href="#rid59">59</a>]. </p><p class="headingAnchor" id="H3357058844"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113059.html" rel="external">"Society guideline links: Cryptococcosis"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for cryptococcal disease</strong> − Most patients with cryptococcal meningoencephalitis are immunocompromised. The most common forms of immunosuppression other than HIV include glucocorticoid therapy, biologic modifiers, the use of some tyrosine kinase inhibitors (eg, <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">ibrutinib</a>), solid organ transplantation, cancer (particularly hematologic malignancy), and conditions such as sarcoidosis and hepatic failure. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> − Treatment of cryptococcal meningoencephalitis consists of antifungal therapy (induction, consolidation, and maintenance phases), managing intracranial pressure, and reducing immunosuppressive therapy. (See <a class="local">'General Principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred antifungal therapy</strong> − For nonpregnant adults with meningoencephalitis, or severe pulmonary or disseminated disease:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest combination therapy with amphotericin B <strong>plus</strong> <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> during the induction phase of treatment (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). We prefer a lipid formulation rather than <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> to reduce toxicity and minimize the risk of treatment interruptions. <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">Liposomal amphotericin B</a> (3 to 4 mg/kg intravenously [IV] per day) or <a class="drug drug_general" data-topicid="8724" href="/z/d/drug information/8724.html" rel="external">amphotericin B lipid complex</a> (5 mg/kg IV per day) can be used. (See <a class="local">'Preferred regimen'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The minimum duration of induction therapy with amphotericin B and <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> is two weeks. However, the ultimate duration depends upon the presence of serious neurologic complications (eg, persistent headaches, seizures, ocular and auditory manifestations), radiographic evidence of brain parenchymal involvement (eg, cryptococcomas), the patient's underlying condition, and the response to therapy (eg, clinical improvement, and, in some cases, the presence or absence of fungal growth on a lumbar puncture performed at two weeks). (See <a class="local">'Duration of preferred regimen'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Following induction therapy, we recommend consolidation therapy with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Fluconazole 800 mg (or 12 mg/kg in children) orally daily should be administered for eight weeks, followed by maintenance therapy with fluconazole (200 to 400 mg orally daily) [<a href="#rid1">1</a>]. Maintenance azole therapy is generally given for one year after diagnosis. (See <a class="local">'Consolidation and maintenance therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Special populations</strong> − There are special considerations regarding the choice of agent and duration of treatment for patients who cannot tolerate first-line agents, as well as for pregnant women, children, and those who present with cryptococcomas. (See <a class="local">'Alternative regimens'</a> above and <a class="local">'Special populations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Control of intracranial pressure</strong> − Control of intracranial pressure is one of the most critical determinants of outcome for cryptococcal meningoencephalitis. The intracranial pressure should be measured at the time of initial lumbar puncture. If the pressure is ≥25 cm of cerebrospinal fluid (CSF) and there are symptoms of increased intracranial pressure during induction therapy, CSF drainage should be performed to reduce the pressure by 50 percent or to a normal pressure of ≤20 cm. (See <a class="local">'Control of intracranial pressure'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Modulating immunosuppression</strong> − Reduction in immunosuppressive therapy may be beneficial for control of cryptococcal infection, although this must be balanced with the potential for organ rejection and immune reconstitution. (See <a class="local">'Modulating immunosuppression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation of persistent or worsening symptoms</strong> − For patients with persistent or worsening symptoms, distinguishing between persistent or relapsed cryptococcal infection, immune reconstitution inflammatory syndrome (IRIS), and other infections or complications can be difficult. The most important distinguishing feature is that patients with active infection have positive CSF cultures, whereas patients with IRIS have sterile CSF cultures. (See <a class="local">'Persistent/worsening symptoms'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Managing persistent or relapsed infection</strong> − Initial management of persistent or relapsed infection should include evaluation of immunosuppressive therapy and management of increased intracranial pressure. Repeat induction phase therapy should be reinstituted for a longer course (4 to 10 weeks) and a surveillance lumbar puncture should be performed after two weeks of therapy. Salvage consolidation therapy depends upon in vitro susceptibility testing. (See <a class="local">'Persistent or relapsed infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Managing IRIS</strong> − Patients with IRIS should continue antifungal therapy. Those with minor manifestations can be managed with supportive care; symptoms frequently resolve spontaneously in days to weeks. In the setting of central nervous system inflammation with increased intracranial pressure and severe symptoms, oral glucocorticoids may be used. (See <a class="local">'Immune reconstitution inflammatory syndrome'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:291.</a></li><li><a class="nounderline abstract_t">Singh N, Dromer F, Perfect JR, Lortholary O. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis 2008; 47:1321.</a></li><li><a class="nounderline abstract_t">Sun HY, Alexander BD, Lortholary O, et al. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis 2009; 49:1721.</a></li><li><a class="nounderline abstract_t">Baddour LM, Perfect JR, Ostrosky-Zeichner L. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis 2005; 40 Suppl 6:S409.</a></li><li><a class="nounderline abstract_t">Bratton EW, El Husseini N, Chastain CA, et al. Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis. Antimicrob Agents Chemother 2013; 57:2485.</a></li><li><a class="nounderline abstract_t">Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 363:1764.</a></li><li><a class="nounderline abstract_t">van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997; 337:15.</a></li><li><a class="nounderline abstract_t">Day JN, Chau TT, Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 2013; 368:1291.</a></li><li><a class="nounderline abstract_t">Molloy SF, Kanyama C, Heyderman RS, et al. Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. N Engl J Med 2018; 378:1004.</a></li><li><a class="nounderline abstract_t">Dromer F, Mathoulin-Pélissier S, Launay O, et al. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 2007; 4:e21.</a></li><li><a class="nounderline abstract_t">Dromer F, Bernede-Bauduin C, Guillemot D, et al. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One 2008; 3:e2870.</a></li><li><a class="nounderline abstract_t">Jarvis JN, Bicanic T, Loyse A, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis 2014; 58:736.</a></li><li><a class="nounderline abstract_t">Igel HJ, Bolande RP. Humoral defense mechanisms in cryptococcosis: substances in normal human serum, saliva, and cerebrospinal fluid affecting the growth of Cryptococcus neoformans. J Infect Dis 1966; 116:75.</a></li><li><a class="nounderline abstract_t">Singh N, Lortholary O, Alexander BD, et al. Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection. Transplantation 2005; 80:1033.</a></li><li><a class="nounderline abstract_t">Bratton EW, El Husseini N, Chastain CA, et al. Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. PLoS One 2012; 7:e43582.</a></li><li><a class="nounderline abstract_t">Zonios DI, Falloon J, Huang CY, et al. Cryptococcosis and idiopathic CD4 lymphocytopenia. Medicine (Baltimore) 2007; 86:78.</a></li><li><a class="nounderline abstract_t">Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001; 33:690.</a></li><li><a class="nounderline abstract_t">Dismukes WE, Cloud G, Gallis HA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987; 317:334.</a></li><li><a class="nounderline abstract_t">Hamill RJ, Sobel JD, El-Sadr W, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis 2010; 51:225.</a></li><li><a class="nounderline abstract_t">Rex JH, Larsen RA, Dismukes WE, et al. Catastrophic visual loss due to Cryptococcus neoformans meningitis. Medicine (Baltimore) 1993; 72:207.</a></li><li><a class="nounderline abstract_t">Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994; 19:741.</a></li><li><a class="nounderline abstract_t">Mayanja-Kizza H, Oishi K, Mitarai S, et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis 1998; 26:1362.</a></li><li><a class="nounderline abstract_t">Milefchik E, Leal MA, Haubrich R, et al. Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol 2008; 46:393.</a></li><li><a class="nounderline abstract_t">Ely EW, Peacock JE Jr, Haponik EF, Washburn RG. Cryptococcal pneumonia complicating pregnancy. Medicine (Baltimore) 1998; 77:153.</a></li><li><a class="nounderline abstract_t">Annapureddy SR, Masterson SW, David HG, Greig JR. Post partum osteomyelitis due to Cryptococcus neoformans. Scand J Infect Dis 2007; 39:354.</a></li><li><a class="nounderline abstract_t">Singh N, Perfect JR. Immune reconstitution syndrome and exacerbation of infections after pregnancy. Clin Infect Dis 2007; 45:1192.</a></li><li><a class="nounderline abstract_t">Dean JL, Wolf JE, Ranzini AC, Laughlin MA. Use of amphotericin B during pregnancy: case report and review. Clin Infect Dis 1994; 18:364.</a></li><li><a class="nounderline abstract_t">Mueller M, Balasegaram M, Koummuki Y, et al. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. J Antimicrob Chemother 2006; 58:811.</a></li><li><a class="nounderline abstract_t">King CT, Rogers PD, Cleary JD, Chapman SW. Antifungal therapy during pregnancy. Clin Infect Dis 1998; 27:1151.</a></li><li><a class="nounderline abstract_t">Tiboni GM. Second branchial arch anomalies induced by fluconazole, a bis-triazole antifungal agent, in cultured mouse embryos. Res Commun Chem Pathol Pharmacol 1993; 79:381.</a></li><li><a class="nounderline abstract_t">Pursley TJ, Blomquist IK, Abraham J, et al. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996; 22:336.</a></li><li class="breakAll">American Academy of Pediatrics. Cryptococcus neoformans and Cryptococcus gattii Infections (Cryptococcosis). In: In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32, American Academy of Pediatrics, Itasca, IL 2021. p.285.</li><li><a class="nounderline abstract_t">Soltani M, Tobin CM, Bowker KE, et al. Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory. Int J Antimicrob Agents 2006; 28:574.</a></li><li><a class="nounderline abstract_t">Gonzalez CE, Shetty D, Lewis LL, et al. Cryptococcosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996; 15:796.</a></li><li><a class="nounderline abstract_t">Manfredi R, Coronado OV, Mastroianni A, Chiodo F. Liposomal amphotericin B and recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) in the treatment of paediatric AIDS-related cryptococcosis. Int J STD AIDS 1997; 8:406.</a></li><li><a class="nounderline abstract_t">Athanassiadou F, Tragiannidis A, Papageorgiou T, Velegraki A. Fungal brain abscesses in leukemia. Indian Pediatr 2006; 43:991.</a></li><li><a class="nounderline abstract_t">Lee JW, Seibel NL, Amantea M, et al. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr 1992; 120:987.</a></li><li><a class="nounderline abstract_t">Seay RE, Larson TA, Toscano JP, et al. Pharmacokinetics of fluconazole in immune-compromised children with leukemia or other hematologic diseases. Pharmacotherapy 1995; 15:52.</a></li><li><a class="nounderline abstract_t">Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995; 21:28.</a></li><li><a class="nounderline abstract_t">Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995; 20:611.</a></li><li><a class="nounderline abstract_t">Ecevit IZ, Clancy CJ, Schmalfuss IM, Nguyen MH. The poor prognosis of central nervous system cryptococcosis among nonimmunosuppressed patients: a call for better disease recognition and evaluation of adjuncts to antifungal therapy. Clin Infect Dis 2006; 42:1443.</a></li><li><a class="nounderline abstract_t">Chen S, Sorrell T, Nimmo G, et al. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis 2000; 31:499.</a></li><li><a class="nounderline abstract_t">Waterston JA, Gilligan BS. Cryptococcal infections of the central nervous system: a ten year experience. Clin Exp Neurol 1987; 23:127.</a></li><li><a class="nounderline abstract_t">Brouwer AE, Siddiqui AA, Kester MI, et al. Immune dysfunction in HIV-seronegative, Cryptococcus gattii meningitis. J Infect 2007; 54:e165.</a></li><li><a class="nounderline abstract_t">Hospenthal DR, Bennett JE. Persistence of cryptococcomas on neuroimaging. Clin Infect Dis 2000; 31:1303.</a></li><li><a class="nounderline abstract_t">Blackie JD, Danta G, Sorrell T, Collignon P. Ophthalmological complications of cryptococcal meningitis. Clin Exp Neurol 1985; 21:263.</a></li><li><a class="nounderline abstract_t">Park MK, Hospenthal DR, Bennett JE. Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Clin Infect Dis 1999; 28:629.</a></li><li><a class="nounderline abstract_t">Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000; 30:47.</a></li><li><a class="nounderline abstract_t">Macsween KF, Bicanic T, Brouwer AE, et al. Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: case report and review. J Infect 2005; 51:e221.</a></li><li><a class="nounderline abstract_t">Pappas PG. Managing cryptococcal meningitis is about handling the pressure. Clin Infect Dis 2005; 40:480.</a></li><li><a class="nounderline abstract_t">Woodworth GF, McGirt MJ, Williams MA, Rigamonti D. The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegally secondary to HIV-associated cryptococcal meningitis. Surg Neurol 2005; 63:529.</a></li><li><a class="nounderline abstract_t">Newton PN, Thai le H, Tip NQ, et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis 2002; 35:769.</a></li><li><a class="nounderline abstract_t">Singh N, Lortholary O, Alexander BD, et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 2005; 40:1756.</a></li><li><a class="nounderline abstract_t">Singh N, Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 2007; 7:395.</a></li><li><a class="nounderline abstract_t">Kontoyiannis DP, Lewis RE, Alexander BD, et al. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother 2008; 52:735.</a></li><li><a class="nounderline abstract_t">Singh N, Alexander BD, Lortholary O, et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007; 195:756.</a></li><li><a class="nounderline abstract_t">Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19:399.</a></li><li><a class="nounderline abstract_t">Rhein J, Bahr NC, Hemmert AC, et al. Diagnostic performance of a multiplex PCR assay for meningitis in an HIV-infected population in Uganda. Diagn Microbiol Infect Dis 2016; 84:268.</a></li><li><a class="nounderline abstract_t">Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med 1974; 80:176.</a></li><li><a class="nounderline abstract_t">Witt MD, Lewis RJ, Larsen RA, et al. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin Infect Dis 1996; 22:322.</a></li><li><a class="nounderline abstract_t">Thompson GR 3rd, Rendon A, Ribeiro Dos Santos R, et al. Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. Clin Infect Dis 2016; 63:356.</a></li><li><a class="nounderline abstract_t">Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122.</a></li><li><a class="nounderline abstract_t">Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005; 56:745.</a></li><li><a class="nounderline abstract_t">Pappas PG, Bustamante B, Ticona E, et al. Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004; 189:2185.</a></li><li><a class="nounderline abstract_t">Jarvis JN, Meintjes G, Rebe K, et al. Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 2012; 26:1105.</a></li><li><a class="nounderline abstract_t">Beardsley J, Wolbers M, Kibengo FM, et al. Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis. N Engl J Med 2016; 374:542.</a></li><li><a class="nounderline abstract_t">Ingram PR, Howman R, Leahy MF, Dyer JR. Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy. Clin Infect Dis 2007; 44:e115.</a></li><li><a class="nounderline abstract_t">Sun HY, Singh N. Opportunistic infection-associated immune reconstitution syndrome in transplant recipients. Clin Infect Dis 2011; 53:168.</a></li><li><a class="nounderline abstract_t">Sun HY, Alexander BD, Huprikar S, et al. Predictors of immune reconstitution syndrome in organ transplant recipients with cryptococcosis: implications for the management of immunosuppression. Clin Infect Dis 2015; 60:36.</a></li><li><a class="nounderline abstract_t">Panackal AA, Komori M, Kosa P, et al. Spinal Arachnoiditis as a Complication of Cryptococcal Meningoencephalitis in Non-HIV Previously Healthy Adults. Clin Infect Dis 2017; 64:275.</a></li><li><a class="nounderline abstract_t">Spec A, Raval K, Powderly WG. End-Stage Liver Disease Is a Strong Predictor of Early Mortality in Cryptococcosis. Open Forum Infect Dis 2016; 3:ofv197.</a></li><li><a class="nounderline abstract_t">Williamson PR. Post-infectious inflammatory response syndrome (PIIRS): Dissociation of T-cell-macrophage signaling in previously healthy individuals with cryptococcal fungal meningoencephalitis. Macrophage (Houst) 2015; 2.</a></li><li><a class="nounderline abstract_t">Panackal AA, Wuest SC, Lin YC, et al. Paradoxical Immune Responses in Non-HIV Cryptococcal Meningitis. PLoS Pathog 2015; 11:e1004884.</a></li><li><a class="nounderline abstract_t">White M, Cirrincione C, Blevins A, Armstrong D. Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. J Infect Dis 1992; 165:960.</a></li><li><a class="nounderline abstract_t">Saijo T, Chen J, Chen SC, et al. Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients. MBio 2014; 5:e00912.</a></li></ol></div><div id="topicVersionRevision">Topic 2443 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20047480" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18840080" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cryptococcosis in solid organ transplant recipients: current state of the science.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19886800" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15809927" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Successful use of amphotericin B lipid complex in the treatment of cryptococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23478968" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15172774" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9203426" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23550668" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Combination antifungal therapy for cryptococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29539274" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17284154" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18682846" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Major role for amphotericin B-flucytosine combination in severe cryptococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24319084" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5908853" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Humoral defense mechanisms in cryptococcosis: substances in normal human serum, saliva, and cerebrospinal fluid affecting the growth of Cryptococcus neoformans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16278582" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22937064" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17435588" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cryptococcosis and idiopathic CD4 lymphocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11477526" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3299095" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20536366" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8341139" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Catastrophic visual loss due to Cryptococcus neoformans meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7803641" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9636863" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18415850" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9653427" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cryptococcal pneumonia complicating pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17454902" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Post partum osteomyelitis due to Cryptococcus neoformans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17918082" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Immune reconstitution syndrome and exacerbation of infections after pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8011817" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Use of amphotericin B during pregnancy: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16916865" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9827262" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Antifungal therapy during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8480084" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Second branchial arch anomalies induced by fluconazole, a bis-triazole antifungal agent, in cultured mouse embryos.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8838193" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Fluconazole-induced congenital anomalies in three infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8838193" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Fluconazole-induced congenital anomalies in three infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17085019" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8878224" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cryptococcosis in human immunodeficiency virus-infected children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9179655" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Liposomal amphotericin B and recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) in the treatment of paediatric AIDS-related cryptococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17151404" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Fungal brain abscesses in leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1593362" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Safety and pharmacokinetics of fluconazole in children with neoplastic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7739946" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pharmacokinetics of fluconazole in immune-compromised children with leukemia or other hematologic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7578756" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical and host differences between infections with the two varieties of Cryptococcus neoformans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7756484" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16619158" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The poor prognosis of central nervous system cryptococcosis among nonimmunosuppressed patients: a call for better disease recognition and evaluation of adjuncts to antifungal therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10987712" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3665161" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cryptococcal infections of the central nervous system: a ten year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17109966" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Immune dysfunction in HIV-seronegative, Cryptococcus gattii meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11073772" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Persistence of cryptococcomas on neuroimaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3843225" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Ophthalmological complications of cryptococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10194090" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10619732" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16291274" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668875" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Managing cryptococcal meningitis is about handling the pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15936373" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegally secondary to HIV-associated cryptococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12203177" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15909263" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17521592" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Immune reconstitution syndrome associated with opportunistic mycoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18070977" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17262720" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15750393" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26711635" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Diagnostic performance of a multiplex PCR assay for meningitis in an HIV-infected population in Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4811791" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prognostic factors in cryptococcal meningitis. A study in 111 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8838190" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27169478" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12715306" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Voriconazole treatment for less-common, emerging, or refractory fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135526" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Activity of posaconazole in the treatment of central nervous system fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15181565" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22421244" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Adjunctive interferon-γimmunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26863355" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17516390" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21690625" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Opportunistic infection-associated immune reconstitution syndrome in transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25210020" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Predictors of immune reconstitution syndrome in organ transplant recipients with cryptococcosis: implications for the management of immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28011613" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Spinal Arachnoiditis as a Complication of Cryptococcal Meningoencephalitis in Non-HIV Previously Healthy Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26835475" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : End-Stage Liver Disease Is a Strong Predictor of Early Mortality in Cryptococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27064474" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Post-infectious inflammatory response syndrome (PIIRS): Dissociation of T-cell-macrophage signaling in previously healthy individuals with cryptococcal fungal meningoencephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26020932" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Paradoxical Immune Responses in Non-HIV Cryptococcal Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1569350" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24643864" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
